Tumor immunotherapy is undoubtedly one of the most promising trends in anti-tumor drug research worldwide. With the NDA approval of anti-tumor innovative drugs based on the hot targets like CAR-T, PD-1, PD-L1, CTLA-4 etc., the tumor immune drugs development is rapidly expanding, and the market competition is constantly intensifying. How to accelerate the growth of tumor immune drugs and improve the passing rate of clinical trials? Preclinical development plays a vital role, especially in the efficacy and safety evaluation, which provides reliable data support for clinical trials.
Against this background, Cyagen is inviting industry experts worldwide to discuss the challenges and practices of preclinical research on Immuno-oncology.
During this webinar, our speakers will touch on a range of Immuno-oncology-related key points, including:
Cyagen is a 700-employee company headquartered in Santa Clara, California, with additional Japan and production facilities in China. As a one-stop-shop for research model solutions, Cyagen offers a broad portfolio of custom genetically engineered models, ready-to-use catalog models, and drug development models - specifically tailored to the unique needs of drug development studies.
Our comprehensive services cover the entire process of animal model generation: from transgenic/gene targeting strategy design to animal model development, breeding, cryopreservation, and animal phenotype analysis. In addition, our virus products and services are widely used in the construction of various cell models, in vivo injection of living animals, gene therapy, and other research fields.